Business
Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board
Dr. Lacouture will oversee the development of Hoth's Proprietary HT-001 for patients receiving EGFR inhibitor cancer treatment. NEW YORK, Jan. 27, 2021
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Dr. Lacouture will oversee the development of Hoth's Proprietary HT-001 for patients receiving EGFR inhibitor cancer treatment.\n\n\nNEW YORK, Jan. 27, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), (\"Hoth\" or the \"Company\"), a biopharmaceutical company, today announced the addition of Mario Lacouture, M.D. to the Company's Scientific Advisory Board. \n\n \n \n \n \n \n \n\n \nWhile serving on the Board, Dr, Lacouture will oversee the development of HT-001, a topical therapeutic designed for the treatment of rash and skin disorders associated with initial and repeat courses of epidermal growth factor receptor (EGFR) inhibitor therapy. \nMr. Robb Knie, CEO of Hoth Therapeutics, commented, \"Hoth is extremely pleased to welcome Dr. Lacouture to our Scientific Advisory Board. Dr. Lacouture is a leader and pioneer in the treatment of skin toxicities during cancer therapy and his expertise will be invaluable towards the progression of our HT-001 therapeutic. We look forward to leveraging his wealth of experience as we plan our clinical program for HT-001.\"\nDr. Lacouture is an Attending Physician and the Director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center and a Professor in the Department of Dermatology, Weill Cornell Medicine in New York City. He completed his postdoctoral work at Brigham and Women's Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL. He received his M.D. degree from Javeriana University in Bogota, Colombia, where he grew up. Dr. Lacouture pioneered the discipline of Oncodermatology, which studies and treats dermatologic conditions in cancer patients, and those that arise as a consequence of chemotherapy and/or radiotherapy or stem cell transplants. Dr. Lacouture is currently the Principal Investigator for \"The CHANCE Trial\", A Longitudinal Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women with Non-Metastatic Breast Cancer and a NIH funded study to identify the mechanisms of immune-related cutaneous adverse events. In addition, Dr Lacouture is the principal investigator for various therapeutic trials in oncodermatology. Dr. Lacouture is a well-known lecturer in the US and abroad on der...